放免联合时序在食管癌中的研究进展  

Progress of radioimmunoassay combined with timing in esophageal cancer

作　　者：魏卓隽 汪琳 王瑞琪 王雨 陈焕 徐裕金[2] WEI Zhuojun;WANG Lin;WANG Ruiqi;WANG Yu;CHEN Huan;XU Yujin(School of Medicine,Shaoring University,Shaoring,Zhejiang 312000,China;Department of Thoracic Radiotherapy,Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou,Zhejiang 310022,China;Postgraduate training base Alliance of Wenzhou Medical University(Zhejiang Cancer Hospital),Wenzhou,Zhejiang325035,China;The Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou,Zhejiang 310053,China)

机构地区：[1]绍兴文理学院医学院,浙江绍兴312000 [2]浙江省肿瘤医院胸部放疗科,中国科学院杭州医学研究所,浙江杭州310022 [3]温州医科大学研究生培养基地(浙江省肿瘤医院),浙江温州325035 [4]浙江中医药大学第二临床医学院,浙江杭州310053

出　　处：《中华肿瘤防治杂志》2024年第16期1015-1020,共6页Chinese Journal of Cancer Prevention and Treatment

基　　金：浙江省基础公益研究计划(LGF21H160005);浙江省卫生健康科技计划(2022KY106)。

摘　　要：目的总结食管癌放免联合的相关研究,探讨放免联合的时序问题。方法以食管肿瘤、放射治疗、免疫检查点抑制剂、时序等为中文关键词,以“Esophageal cancer、Radiotherapy、Immune checkpoint inhibitors、Sequence”为英文关键词,检索PubMed、CNKI和百链数据库2011-2022年相关文献。纳入标准:(1)放疗联合免疫治疗机制;(2)食管癌放射和免疫联合治疗。排除标准:(1)数据陈旧文献;(2)内容相似或重复。最终纳入文献49篇。结果基础研究表明,放疗联合免疫治疗可以通过改善肿瘤微环境、诱导免疫抗原暴露、增加肿瘤细胞含氧量等方式增强对肿瘤细胞的杀伤作用。食管癌临床试验表明,无论放疗前免疫还是放疗后免疫均对患者产生生存获益。结论放疗联合免疫治疗可改善食管癌患者预后且安全性良好,而最佳的联合时序仍有待探讨。Objective To summarize studies related to radiation-immunity combinations in esophageal cancer and to explore the timing of radiation-immunity combinations.Methods PubMed database,CNKI database,and BaiLian database were searched by using the keywords"Esophageal cancer,Radiotherapy,Immune checkpoint inhibitors,Sequence"for relevant literature from 201l to 2022.Inclusion criteria:(1)radiotherapy combined with immunotherapy as the mechanism of treatment;(2)combined radiotherapy and immunotherapy for esophageal cancer.Exclusion criteria:(1)literature with obsolete data;(2)content similarity or duplication.A total of 49 papers were finally included.Results Basic research has shown that radiotherapy combined with immunotherapy can enhance the killing effect on tumor cells by improving the tumor microenvironment,inducing immune antigen exposure,and increasing the oxygen content of tumor cells.Clinical trials in esophageal cancer have shown that both immunotherapy prior to radiotherapy and immunotherapy after radiation therapy produce survival benefits for patients.Conclusion Radiotherapy combined with immunotherapy can significantly improve the prognosis of patients with esophageal cancer and has a positive safety profile,while the sequence of combinationremainstobe explored.

关 键 词：食管肿瘤 放射治疗 免疫检查点抑制剂 时序 综述文献 

分 类 号：R735.1[医药卫生—肿瘤]